State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of approximately 7% of Sarepta Therapeutics Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 7,412,275 shares of Sarepta Therapeutics Inc. common stock.
  • Percent of class: The filing states the aggregate amount represents 7% of the class.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote for 7,135,106 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared power to dispose of 7,412,275 shares, with sole dispositive power of 0.
  • Filing event date: The date of the event requiring this filing is listed as September 30, 2026.
  • Reporting subsidiaries: The filing identifies six State Street subsidiaries classified as investment advisers, including SSGA Funds Management, Inc. and State Street Global Advisors Trust Company, among others.

State Street Corporation's Disclosed Position in Sarepta Therapeutics

According to the Schedule 13G filed November 10, 2026, State Street Corporation, a holding company organized in Massachusetts with its principal business office at One Congress Street, Suite 1, Boston, MA 02114, reported beneficial ownership of 7,412,275 shares of common stock in Sarepta Therapeutics Inc. (CUSIP 803607100). Sarepta Therapeutics Inc. is located at 215 First Street, Suite 415, Cambridge, Massachusetts, 02142, according to the filing.

The filing classifies State Street Corporation as a parent holding company or control person under Item 3(g). State Street disclosed zero sole voting power and zero sole dispositive power. Shared voting power is reported as 7,135,106 shares, while shared dispositive power covers the full 7,412,275 shares reported as the aggregate beneficial ownership amount. The filing identifies six subsidiaries through which the position is held, all classified as investment advisers (IA): SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Singapore Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd.

The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026. The certification included in Item 10 states that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities."

What Was Disclosed

State Street Corporation filed a Schedule 13G disclosing beneficial ownership of 7,412,275 shares, or 7%, of Sarepta Therapeutics Inc. common stock, with the triggering event dated September 30, 2026, and six investment adviser subsidiaries identified as the acquiring entities.